Thalidomide therapy for granulomatous interstitial pneumonia in patients with chronic granulomatous disease
-
- Kawai Toshinao
- Department of Human Genetics, National Center for Child Health and Development Division of Immunology, National Center for Child Health and Development
-
- Watanabe Nobuyuki
- Division of Immunology, National Center for Child Health and Development
-
- Yokoyama Midori
- Division of Immunology, National Center for Child Health and Development
-
- Nakazawa Yumiko
- Department of Human Genetics, National Center for Child Health and Development Division of Immunology, National Center for Child Health and Development
-
- Goto Fumihiro
- Department of Human Genetics, National Center for Child Health and Development Division of Immunology, National Center for Child Health and Development
-
- Uchiyama Toru
- Department of Human Genetics, National Center for Child Health and Development Division of Immunology, National Center for Child Health and Development
-
- Maekawa Takanobu
- Department of Pediatrics, National Center for Child Health and Development
-
- Higuchi Masataka
- Division of Pulmonology, National Center for Child Health and Development
-
- Hojo Masayuki
- Division of Respiratory Medicine, National Center for Global Health and Medicine Japan
-
- Onodera Masafumi
- Department of Human Genetics, National Center for Child Health and Development Division of Immunology, National Center for Child Health and Development
Bibliographic Information
- Other Title
-
- 慢性肉芽腫症に合併した肉芽腫性間質性肺炎に対するサリドマイド治療
- 慢性肉芽腫症に合併した肉芽腫性同質性肺炎に対するサリドマイド治療
- マンセイ ニクガシュショウ ニ ガッペイ シタ ニクガシュセイ ドウシツセイ ハイエン ニ タイスル サリドマイド チリョウ
Search this article
Description
Chronic granulomatous disease(CGD)is a primary immunodeficiency characterized by an inability of phagocytes to produce reactive oxygen species, resulting in recurrent life-threatening infections. Although CGD patients frequently develop inflammatory granuloma due to prolonged production of inflammatory cytokines, the treatment with corticosteroid and immunosuppressive drugs are limited because the anti-inflammation therapy for granuloma formation would increase susceptibility to infection in CGD. Herein we described two CGD patients who suffered from granulomatous interstitial pneumonia (GIP) and received thalidomide therapy for three months. Their serum level of KL-6 was high and CT lung images showed increased reticulonodular opacities. Pathological findings for GIP patient reveal inflammation and micro-granuloma formation of interstitial lung tissue, which are similar to those of hypersensitivity pneumonia. Reticulo-nodular opacities on CT image were disappeared and the KL-6 1evels were reduced after three months of thalidomide therapy in CGD patients with GIP.Although further works are required,our findings suggest that thalidomide therapy would be therapeutic effect on pulmonary inflammatory granuloma in the CGD patients.
Journal
-
- The Journal of Clinical Pediatric Rheumatology
-
The Journal of Clinical Pediatric Rheumatology 6 (1), 11-16, 2015
Pediatric Rheumatology Association of Japan
- Tweet
Details 詳細情報について
-
- CRID
- 1391694356243706240
-
- NII Article ID
- 130007956758
-
- NII Book ID
- AA12708652
-
- ISSN
- 2434608X
- 24351105
-
- NDL BIB ID
- 027448406
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- NDL Search
- CiNii Articles
- KAKEN
-
- Abstract License Flag
- Disallowed